First Amendment to License Agreement, by and among the Registrant and BioCryst Pharmaceuticals, Inc., dated as of May 20, 2024

Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both (a) not material and (b) the type that the registrant customarily and actually treats as private or confidential.

AMENDMENT 1 TO THE LICENSE AGREEMENT

THIS FIRST AMENDMENT to the LICENSE AGREEMENT (the “Amendment”) is made and entered into on this 20th day of May 2024 (the “Amendment Effective Date”), by and between BioCryst Pharmaceuticals, Inc. (“BioCryst”) and Clearside Biomedical, Inc. (“Clearside”). All undefined terms contained herein shall have the meaning set forth in the Agreement.

RECITALS

WHEREAS, BioCryst and Clearside entered into the License Agreement having an effective date of November 1, 2023 (the “Agreement”);

WHEREAS, the Parties now wish to amend the Agreement in consideration of the mutual terms, conditions, and covenants hereinafter set forth.

NOW, THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, BioCryst and Clearside, intending to be legally bound, have agreed to amend the terms of the Agreement as follows:

“1.100 [***]”

IN WITNESS WHEREOF, the parties have executed this Amendment as of the Amendment Effective Date.